Výsledky vyhledávání - "Enrica Alteri"

Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs

Autor: Giampiero Mazzaglia, Daniela da Silva, Enrica Alteri, Heidi Janssen, June Raine, Sabine M. J. M. Straus, Peter Arlett

Publikováno v: Drug Safety
Drug Safety, 41(2), 191-202. Adis

Introduction Studies measuring the effectiveness of risk minimization measures (RMMs) submitted by pharmaceutical companies to the European Medicines Agency are part of the post-authorization regulatory requirements and represent an important source

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9443b147b9623bf036ca0e03ba8301
https://doi.org/10.1007/s40264-017-0604-4

Zobrazit plný text záznamu

Be open about drug failures to speed up research

Autor: Enrica Alteri, Lorenzo Guizzaro

Publikováno v: Nature. 563:317-319

Access to evidence from disappointing drug-development programmes advances the whole scientific process, explain Enrica Alteri and Lorenzo Guizzaro. Access to evidence from disappointing drug-development programmes advances the whole scientific proce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10dacf614fbf9df6aeab799d18f57b37
https://doi.org/10.1038/d41586-018-07352-7

Zobrazit plný text záznamu

Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple Sclerosis

Autor: Graham Wetherill, Enrica Alteri, Gordon S. Francis, Paul O'Connor, Peter Rieckmann

Publikováno v: Drug Safety. 27:745-756

Introduction Interferon-beta-1a (Rebif) is an established treatment for relapsing-remitting multiple sclerosis (MS) and haematological changes are commonly reported in clinical trials of this agent. The combined clinical trial and postmarketing safet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8aff5c1e84875ac0b5902f56393187
https://doi.org/10.2165/00002018-200427100-00005

Zobrazit plný text záznamu

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings

Autor: Magnhild, Sandberg-Wollheim, Gabrielle, Kornmann, Dorina, Bischof, Margaretha Stam, Moraga, Brian, Hennessy, Enrica, Alteri

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England). 17(4)

Risks that are potentially associated with long-term therapies should be assessed.The present analyses were performed to determine the risk of malignancy in patients with multiple sclerosis (MS) receiving subcutaneous (sc) interferon (IFN) beta-1a, u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a97aef6247722de946bcf49533c90f00
https://pubmed.ncbi.nlm.nih.gov/21486902

Zobrazit plný text záznamu

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings

Autor: Brian Hennessy, Margaretha Stam Moraga, Dorina Bischof, Gabrielle Kornmann, Enrica Alteri, Magnhild Sandberg-Wollheim

Publikováno v: Multiple Sclerosis Journal; 17(4), pp 431-440 (2011)

Background: Risks that are potentially associated with long-term therapies should be assessed. Objective: The present analyses were performed to determine the risk of malignancy in patients with multiple sclerosis (MS) receiving subcutaneous (sc) int

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6454a5af916373afa81c99dc146ada06
https://lup.lub.lu.se/record/1937221

Zobrazit plný text záznamu

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

Autor: Jonathan Alsop, Alain Micaleff, Gordon S. Francis, Neil Kaplowitz, Yves Grumser, Fanny O’Brien, Enrica Alteri, Margaretha Stam Moraga

Publikováno v: Drug safety. 26(11)

Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited.To retrospectively assess the safety profile of interferon-beta-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::924f7edbbb1169c974b2ce49d4b5db0e
https://pubmed.ncbi.nlm.nih.gov/12908850

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání